Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: Many questions remain unanswered regarding the optimal treatment approach for patients with indolent lymphoma. Randomized phase III trials addressing the key issues in patient management are ongoing. Continued follow-up of treated patients will be required to assess the character and frequency of long-term toxicities, and to provide insights into the best sequencing of treatments. It is likely that combinations of new treatment strategies will have the greatest impact on long-term clinical outcome. New insights into the underlying biology of the indolent lymphomas are anticipated to help guide therapy for individual patients and to provide new therapeutic targets.
|
Authors | Jane N Winter |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 14
Issue 4
Pg. 360-8
(Jul 2007)
ISSN: 1065-6251 [Print] United States |
PMID | 17534162
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Humans
- Immunotherapy
(methods)
- Lymphoma, Non-Hodgkin
(therapy)
- Radioimmunotherapy
(methods)
- Treatment Outcome
|